NovaBay Pharmaceuticals, Inc. (NBY)

NovaBay Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	10.27	9.75	10.46	14.37	10.18	9.92
Other Revenue	0.03	0.03	-	0.03	0.02	0.02
Revenue	10.3	9.78	10.46	14.4	10.2	9.93
Revenue Growth (YoY)	390.34%	-6.45%	-27.42%	41.16%	2.72%	50.54%
Cost of Revenue	3.78	3.3	4.37	6.62	3.69	3.97
Gross Profit	6.52	6.48	6.08	7.78	6.52	5.96
Selling, General & Admin	11.61	11.41	10.15	15.29	15.33	12.11
Research & Development	0.04	0.04	0.03	0.17	0.04	0.29
Operating Expenses	11.65	11.46	10.19	15.46	15.38	12.39
Operating Income	-5.12	-4.97	-4.1	-7.68	-8.86	-6.43
Interest Expense	-0.03	-0.9	-1.69	-	-	-
Other Non Operating Income (Expenses)	-0.29	-0.44	-0.39	3.25	3.04	-5.51
EBT Excluding Unusual Items	-5.44	-6.31	-6.19	-4.43	-5.82	-11.93
Impairment of Goodwill	-	-	-	-4.18	-	-
Gain (Loss) on Sale of Assets	-0.87	-0.87	-	-	-	-
Asset Writedown	-0.68	-	-	-2.56	-	-
Other Unusual Items	-	-0.03	0.04	0.56	-	0.9
Pretax Income	-6.99	-7.21	-6.15	-10.61	-5.82	-11.03
Income Tax Expense	-	-	-	-	-	0.01
Earnings From Continuing Operations	-6.99	-7.21	-6.15	-10.61	-5.82	-11.04
Earnings From Discontinued Operations	10.23	-0.01	-3.5	-	-	-
Net Income	3.24	-7.22	-9.64	-10.61	-5.82	-11.04
Preferred Dividends & Other Adjustments	-	1.39	7.06	5.66	0.74	-
Net Income to Common	3.24	-8.61	-16.7	-16.27	-6.56	-11.04
Shares Outstanding (Basic)	7	3	0	0	0	0
Shares Outstanding (Diluted)	7	3	0	0	0	0
Shares Change (YoY)	831.36%	2730.00%	160.87%	29.11%	24.43%	62.08%
EPS (Basic)	0.47	-2.53	-139.14	-353.59	-184.09	-385.53
EPS (Diluted)	0.47	-2.53	-139.14	-353.59	-184.09	-385.53
Free Cash Flow	2.95	-5.4	-4.65	-6.77	-9.24	-4.75
Free Cash Flow Per Share	0.42	-1.59	-38.77	-147.09	-259.45	-165.79
Gross Margin	63.32%	66.26%	58.19%	54.02%	63.85%	60.04%
Operating Margin	-49.74%	-50.85%	-39.23%	-53.32%	-86.85%	-64.69%
Profit Margin	31.48%	-88.01%	-159.70%	-112.92%	-64.28%	-111.12%
Free Cash Flow Margin	28.66%	-55.16%	-44.51%	-46.97%	-90.59%	-47.78%
EBITDA	-5.1	-4.93	-4.05	-7.2	-8.74	-6.38
EBITDA Margin	-49.53%	-50.44%	-38.75%	-49.96%	-85.68%	-64.17%
D&A For EBITDA	0.02	0.04	0.05	0.48	0.12	0.05
EBIT	-5.12	-4.97	-4.1	-7.68	-8.86	-6.43
EBIT Margin	-49.74%	-50.85%	-39.23%	-53.32%	-86.85%	-64.69%
Revenue as Reported	9.78	9.78	10.46	14.4	10.2	9.93
Advertising Expenses	-	0.7	1.1	2	3.2	1.7

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q